Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N F Frolova

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Arkhiv Patologii|April 19, 2017
[A rare concurrence of polymyalgia rheumatica and AA-amyloidosis]S G Radenska-Lopovok, O N Kotenko, N F Frolova, et al.
Klinicheskaia Meditsina|May 7, 2016
[RHEUTMATIC MYALGIA COMPLICATED BY AA-AMYLOIDOSIS]M L Zubkin, Yu V Ovchinnikov, N F Frolova, et al.
Terapevticheskii Arkhiv|October 26, 2022
[COVID-19 in haemodialysis patients: result analysis of the first year of the pandemic]M L Zubkin, N F Frolova, I G Kim, et al.
Terapevticheskii Arkhiv|October 26, 2022
[Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19]T S Kruglova, D S Fomina, N G Poteshkina, et al.
Terapevticheskii Arkhiv|December 30, 2023
[The burden of COVID-19 in a heterogeneous population of immunocompromised patients - realities of the postpandemic]S N Avdeev, V P Chulanov, E I Alexeeva, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Arkhiv Patologii|April 19, 2017
[A rare concurrence of polymyalgia rheumatica and AA-amyloidosis]S G Radenska-Lopovok, O N Kotenko, N F Frolova, et al.
Klinicheskaia Meditsina|May 7, 2016
[RHEUTMATIC MYALGIA COMPLICATED BY AA-AMYLOIDOSIS]M L Zubkin, Yu V Ovchinnikov, N F Frolova, et al.
Terapevticheskii Arkhiv|October 26, 2022
[COVID-19 in haemodialysis patients: result analysis of the first year of the pandemic]M L Zubkin, N F Frolova, I G Kim, et al.
Terapevticheskii Arkhiv|October 26, 2022
[Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19]T S Kruglova, D S Fomina, N G Poteshkina, et al.
Terapevticheskii Arkhiv|December 30, 2023
[The burden of COVID-19 in a heterogeneous population of immunocompromised patients - realities of the postpandemic]S N Avdeev, V P Chulanov, E I Alexeeva, et al.
Pageof 1